Photosensitivity with sulfasalazopyridine hypersensitivity syndrome.
Five weeks after the start of treatment with an association of sulfasalazopyridine and piroxicam, a 30-year-old woman presented with an eczematous eruption in light-exposed areas, hepatomegaly and fever (38 degrees C). Laboratory studies showed leukocytosis, eosinophilia and hepatic cytolysis. Treatment consisted of withdrawing the two drugs and topical steroids. The clinical signs regressed in 6 days. An increase in eosinophilia and hepatic cytolysis was observed until the tenth day, after which the trend reversed. Laboratory parameters were normal on the twentieth day. One month later, photopatch testing was performed. A patch test with sulfanilamide irradiated with UVA was positive. Clinical and laboratory findings were highly suggestive of drug hypersensitivity syndrome. The positive result from the UVA photopatch test with sulfanilamide suggests that sulfasalazopyridine was involved in the occurrence of hypersensitivity syndrome in our patient. We conclude that photodistributed eruptions can be observed in drug hypersensitivity syndrome with photosensitizing drugs.
Bouyssou-Gauthier
M L
ML
Department of Dermatology, Centre Hospitalier Régional et Universitaire Dupuytren, Limoges, France.
Bédane
C
C
Boulinguez
S
S
Bonnetblanc
J M
JM
D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects* / Q000627:therapeutic use; D015535:Arthritis, Psoriatic / Q000188:drug therapy; D017454:Dermatitis, Photoallergic / Q000209:etiology* / Q000473:pathology; D004342:Drug Hypersensitivity / Q000209:etiology*; D005260:Female; D006801:Humans; D010328:Patch Tests; D012460:Sulfasalazine / Q000009:adverse effects* / Q000627:therapeutic use; D013577:Syndrome
D000894:Anti-Inflammatory Agents, Non-Steroidal; D012460:Sulfasalazine